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Introduction
Classic galactosemia (McKusic 230400) is an inborn error
of galactose metabolism caused by a deficiency of the
enzyme galactose-1-phosphate uridyltransferase (GALT,
EC 2..7.712), resulting in accumulation of the metabolites
galactitol and galactose-1-phosphate. Patients ingesting
galactose from breast milk or infant formula present in the
first weeks of life with feeding difficulties, hepatocellular
dysfunction, hypoglycemia, renal tubular dysfunction,
cataract, and sepsis. Immediate removal of galactose from
the diet results in a full recovery from this life-threatening
neonatal crisis (Holton et al. 2001; Bosch 2006).
Mason and Turner (1935) were the first to report the
successful use of a milk-free diet in an infant with
galactosemia. In the 1950s, different strategies to feed
infants a diet without galactose were discussed in the
literature (Salt et al. 1955; Jones and Leak 1959).
Nowadays, initiating the diet is much easier, as infant
formulas with a very limited amount of galactose are
widely available. Still, there are dilemmas in the treatment
of galactosemia, and the dietary treatment varies widely
around the world. The most troubling issue is that despite a
continued galactose-restricted diet, and irrespective of a
neonatal crisis, many patients suffer from long-term
complications, such as reduced cognitive ability, language
impairment, decreased bone mass, and hypergonadotrophic
hypogonadism in women (Kaufman et al. 1981; Waggoner
et al. 1990; Schweitzer et al. 1993; Panis et al. 2004; Potter
et al. 2008; Schadewaldt et al. 2010).
Infancy
In the first weeks of life, the most important part of
managing patients with classic galactosemia is removing
all galactose from the diet as soon as the diagnosis is
suspected, immediately after starting the diagnostic
investigations and without awaiting results, in order to
prevent further life-threatening complications. Whereas
classic galactosemia is part of the newborn screening
programs of many countries, most children will present
with clinical symptoms, such as feeding problems,
jaundice progressing to liver failure, and sepsis, before
the screening results are available. Infants with classic
galactosemia must be prescribed a galactose-free formu-
la. In The Netherlands, the recommended treatment is
soy milk; in some other countries, infant formula on the
basis of casein hydrolysate and dextrine maltose as
carbohydrate source, such as Nutramigen®, is recom-
mended. The safety of long-term use of soy milk has been
much debated; however, there is no clinical evidence for
harmful effects of this product (Merritt and Jenks 2004; Turck
2007). Both Nutramigen and soy formula still contain very
small amounts of galactose, and recent studies demonstrated
that completely eliminating galactose from the diet by
prescribing an elemental formula (Neocate®) instead of
Nutramigen® or soy formula caused a significantly faster
decrease of the high erythrocyte Gal-1-P values that are
found in infancy in these patients (Ficicioglu et al. 2005;
Zlatunich and Packman 2008). As the time of diagnosis and
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the occurrence of the neonatal crisis do not seem to have a
significant effect on long-term outcome, it remains to be
elucidated whether this rapid decrease would positively
affect outcome, and long-term studies need to be performed
to clarify this before routinely putting these infants on this
expensive and unpalatable formula (Schweitzer-Krantz
2003).
Childhood
With the introduction of solid foods, some galactose will
inevitably be introduced into the diet, as many foods, such
as fruit and vegetables, bread, legumes, and offal, contain
trace amounts of galactose (Gross and Acosta 1991; Acosta
and Gross 1995). Bound galactose is found in many
vegetables as part of raffinose and stachyose. How much
of this bound galactose can be broken down in the gut is
not known. No significant contribution to the intake of
galactose, or effect on biochemical parameters, has been
demonstrated (Wiesmann et al. 1995).
There are major controversies concerning the daily
allowance of galactose during long-term treatment. Many
European metabolic centers recommend a very strict diet,
also restricting galactose containing fruits and vegetables.
Other centers, e.g., in the UK, Germany, The Netherlands,
and the USA, are more liberal, advising only a lactose-free
diet. There is limited knowledge of the tolerance for
exogenous galactose in patients with classic galactosemia.
A newborn infant with galactosemia ingesting 300 ml of
formula or breast milk per day in the first days of life,
equivalent to >7,000 mg of galactose, will develop severe
illness. As soon as the diagnosis is suspected, the galactose
intake will be restricted as much as possible. Patients on a
lactose-free diet with no restrictions of fruit and vegetables
will have a daily intake of galactose <30 mg (Berry et al.
1993; Bosch et al. 2004a). On a diet enriched in fruit and
vegetables, this intake increases to an average of 54 mg of
galactose per day (Berry et al. 1993). In one study, three
adolescents ingested up to 600 mg of galactose per day for
6 weeks without any effect on clinical or laboratory
parameters (Bosch et al. 2004a). Of importance is the
strong contrast between the exogenous intake of galactose
in the lactose-restricted diet, with an average intake of
54 mg of galactose per day with a diet enriched in
galactose-containing fruit and vegetables and the endogenous
production of galactose in adult patients, amounting to
1,000 mg per day (Berry et al. 2004, Huidekoper et al.
2005). This fact is an argument not to restrict fruit and
vegetables from the diet. Also, after the introduction of a less
restricted diet in Australia, no increases in gal-1-p values
were detected (Thompson et al. 2003). Furthermore, in the
UK, where fruit and vegetables are not restricted from the
diet, no new cataracts or liver diseases have been reported in
the literature. It has been demonstrated that the endogenous
production of galactose is not affected by the exogenous
intake from the diet. (Huidekoper et al. 2005)
Adulthood
There is no insight into galactose tolerance of adults
patients with classic galactosemia. Two remarkable
patients have been reported in the literature. A 38-year-
old adult woman and a 34-year-old man, both with
classic galactosemia (Q188R homozygous), had both
discontinued their diet at the age of 3 years (Lee et al.
2003; Panis et al. 2006). Her intake of galactose was
2,690 mg per day, and his daily galactose intake was
9,000 mg. In both patients, there were no signs of cataract
or liver disease, and red cell galactose-1-phosphate and
urine galactitol were within the range of treated galacto-
semics. The female patient had started hormonal replace-
ment therapy at 15 years of age because of primary
amenorrhoea. Her neuropsychological assessment showed
a verbal IQ of 88 and a performance IQ of 78; tests of
attention, memory, and executive functions were below
the tenth percentile for a normal population. The male
patient had an unremarkable neurologic examination and
a normal educational attainment. His in vivo oxidation of
[1-13C] galactose was evaluated and found to be
severely hampered and within the range for treated
patients. These patients’ outcomes seem no worse than
in many patients with classic galactosemia treated with a
strict diet. It is very well possible that the galactose
tolerance of patients with classic galactosemia increases
with age as a result of the age-related decrease of
endogenous galactose production (Berry et al. 2004;
Schadewaldt et al. 2004). It might also be possible that
these patients have a greater capacity to dispose of
galactose by pathways yet unknown. Alternatively, other
factors, such as an aldose reductase deficiency as reported
in the galactosemic mouse, may play a role (Ai et al. 2000;
Segal 2004). In addition, it is not known whether red cell
galactose-1-phosphate or urinary galactitol reflect the
long-term toxicity of galactose in galactosemia. Long-
term exposure to galactose could result in abnormal
galactosylation of glycoproteins and glycolipids, and these
patients might well have had an even better cognitive
outcome if they had continued their diet.
Future perspectives
Based on the theory that exogenous galactose tolerance
increases in adulthood, partly due to the relative decrease in
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endogenous production, relaxation of the galactose-
restricted diet in adulthood might be considered (Berry et
al. 2004; Schadewaldt et al. 2004). A slight relaxation, such
as a lactose-restricted diet without limitations in intake in
fruit and vegetables can very well be justified in the light of
the available evidence and is the standard of care in many
countries. Increasing the daily galactose intake from 27 to
54 mg per day is a minor increase when considering the
fact that an adult will have an endogenous production up to
1,000 mg per day (Berry et al. 2004; Huidekoper et al.
2005). A further relaxation of the diet, however, will cause
a major increase of daily galactose intake. As milk and
milk-containing products such as yoghurt contain 2,400 and
1,800 mg of galactose per 100 mg, respectively, the intake
of even one glass of milk rapidly increases the daily intake
to more than 4,800 mg per day, more than four times the
daily endogenous production. Therefore, full dietary relax-
ation should probably be strongly discouraged until the
pathophysiology behind the long-term complications has
been elucidated and it is clear whether or not this is related
to galactose intake. Long-term studies, preferably after
developing a more valid biochemical marker for
galactose toxicity, evaluating the biochemical and clinical
effects of exogenous galactose in adults as well as in
children, are necessary before any further relaxation of
the diet can be considered.
Even though a lifelong diet will affect the daily lives of
the patients, a lactose-free diet without restriction of fruit
and vegetables is a palatable and not very complicated diet.
Studies have demonstrated that patients with classic
galactosemia have a severely hampered quality of life
(Bosch et al. 2004b). However, it has been demonstrated
that this is the result of the late complications that are found
in many patients and not a result of the diet (Bosch et al.
2009). As the late complications may result from
continuous intoxication by galactose from endogenous
production, dietary relaxation might well increase the
long-term complications by rapidly increasing galactose
load and thus affect patients’ quality of life even more.
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